| Code | CSB-RA013481MB7HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to MK-2214, designed to target MAPT (microtubule-associated protein tau), a critical neuronal protein that stabilizes microtubules in the cytoskeleton of healthy neurons. Under pathological conditions, MAPT undergoes abnormal hyperphosphorylation and aggregation, forming neurofibrillary tangles that are hallmark features of Alzheimer's disease and other tauopathies including frontotemporal dementia, progressive supranuclear palsy, and chronic traumatic encephalopathy. The accumulation of pathological tau species correlates with neurodegeneration and cognitive decline, making MAPT a prime therapeutic target for neurodegenerative disease research.
MK-2214 is a humanized monoclonal antibody developed to selectively target pathological forms of tau protein while sparing normal tau function. This biosimilar provides researchers with a valuable tool for investigating tau biology, protein aggregation mechanisms, and potential therapeutic interventions in tauopathy models. The antibody supports studies examining tau pathology progression, cell-to-cell transmission of misfolded tau, and neuroprotective strategies in neurodegenerative disease research.
There are currently no reviews for this product.